July 2022 Newsletter

ASBM & GaBI Host Non-Medical Switching Webinar On July 20th, 2022 ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a 2-hour webinar entitled “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the US”.  The two-hour event offered an overview of non-medical switching practices in different regions and focused on the importance of safeguarding the patient-physician relationship. […]

Read More


May 2022 Newsletter

Registration Open for June 29th ASBM/GaBI Webinar on Biosimilar Success in Europe and US On June 29th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host a webinar entitled “KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US: measures taken for improving biosimilar uptake and the potential role of healthcare providers and […]

Read More


April 2022 Newsletter

ASBM Submits Comments on Health Canada’s Biosimilar Handbook for HCPs   On April 29th, ASBM submitted comments to Health Canada as part of a stakeholder consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. ASBM’s comments focused on the Handbook’s mixed messaging surrounding biosimilar equivalence and switching, including language which implies inaccurately that Canada’s […]

Read More


March 2022 Newsletter

Health Canada Opens Consultation on Biosimilar Handbook for Healthcare Professionals   Health Canada has opened a consultation on its draft Handbook for healthcare professionals on biosimilar biologic drugs. This publication was developed for the purpose of informing and educating healthcare professionals in Canada regarding biosimilars. The handbook was developed in consultation with a working group composed of […]

Read More


January 2022 Newsletter

ASBM Urges Reform on Copay Accumulator Adjustments   On January 27th, ASBM joined other patient advocacy organizations and physician groups in submitting a coalition letter to the U.S. Department of Health and Human Services (HHS), urging the Department to prohibit the practice of copay accumulator adjustment policies. The coalition letter was submitted as part of the comment period […]

Read More


February 2022

ASBM Shares Physician Perspectives on Non-Medical Switching   In February, ASBM released our latest video, “Non-Medical Switching”, featuring ASBM Chairman Ralph McKibbin, MD.   In the video, Dr. McKibbin shares new data from ASBM’s recent survey of 401 U.S. prescribers of biologics, as well as his own observations on the controversial practice. Among the survey findings: 69% […]

Read More


February 2022

ASBM Shares Physician Perspectives on Non-Medical Switching   In February, ASBM released our latest video, “Non-Medical Switching”, featuring ASBM Chairman Ralph McKibbin, MD.   In the video, Dr. McKibbin shares new data from ASBM’s recent survey of 401 U.S. prescribers of biologics, as well as his own observations on the controversial practice. Among the survey findings: 69% […]

Read More


November 2021

OSU College of Pharmacy Launches ASBM-Developed CE Course on Biologics and Biosimilars   The Ohio State University College of Pharmacy is now offering a 1-hour Continuing Education (CE) course entitled Biologics and Biosimilars: and Introduction. The course is presented by OSU professor and ASBM Advisory Board Chair Philip Schneider, FASHP, FFIP.   The course is […]

Read More


November 2021

OSU College of Pharmacy Launches ASBM-Developed CE Course on Biologics and Biosimilars   The Ohio State University College of Pharmacy is now offering a 1-hour Continuing Education (CE) course entitled Biologics and Biosimilars: and Introduction. The course is presented by OSU professor and ASBM Advisory Board Chair Philip Schneider, FASHP, FFIP.   The course is […]

Read More


December 2021 Newsletter

ASBM Letter to Congress: Paying Physicians to Prescribe Government-Preferred Biosimilars Undermines Patient-Physician Relationship   On December 2nd, ASBM sent a letter to House leaders reiterating our opposition to a proposal that would undermine the patient-physician relationship and distort the making of treatment decisions. The U.S. House of Representatives Committee on Rules has released new language […]

Read More